Novelix Pharmaceuticals Limited (BOM:536565)
India · Delayed Price · Currency is INR 40.99
+0.99 (2.48%)
At close: Aug 5, 2025
Blueprint Medicines Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 307.19 | 42.24 | 14.05 | 86.09 | 92.42 | Upgrade |
Other Revenue | 0.16 | 2.71 | 5.16 | 3.04 | 3.43 | Upgrade |
| 307.34 | 44.95 | 19.2 | 89.13 | 95.85 | Upgrade | |
Revenue Growth (YoY) | 583.80% | 134.06% | -78.45% | -7.01% | -11.60% | Upgrade |
Cost of Revenue | 295.74 | 38.53 | 13.83 | 82.94 | 85.61 | Upgrade |
Gross Profit | 11.61 | 6.42 | 5.38 | 6.18 | 10.24 | Upgrade |
Selling, General & Admin | 0.69 | 1.91 | 3.56 | 5.79 | 9.91 | Upgrade |
Other Operating Expenses | 9.31 | 2.9 | 1.84 | 3.61 | 34.85 | Upgrade |
Operating Expenses | 10.37 | 6.57 | 5.96 | 11 | 46.85 | Upgrade |
Operating Income | 1.23 | -0.15 | -0.58 | -4.82 | -36.61 | Upgrade |
Interest Expense | - | - | - | -0.58 | -0.54 | Upgrade |
Earnings From Equity Investments | - | - | - | 0.87 | -0.23 | Upgrade |
Other Non Operating Income (Expenses) | - | 0 | 0 | - | -0.13 | Upgrade |
EBT Excluding Unusual Items | 1.23 | -0.15 | -0.58 | -4.53 | -37.51 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | -15.6 | - | Upgrade |
Gain (Loss) on Sale of Assets | - | 0.37 | - | -0.23 | - | Upgrade |
Pretax Income | 1.23 | 0.21 | -0.58 | -20.35 | -37.51 | Upgrade |
Income Tax Expense | 0.39 | 0.11 | 0.01 | -0.08 | 0.13 | Upgrade |
Earnings From Continuing Operations | 0.85 | 0.1 | -0.6 | -20.27 | -37.64 | Upgrade |
Net Income | 0.85 | 0.1 | -0.6 | -20.27 | -37.64 | Upgrade |
Net Income to Common | 0.85 | 0.1 | -0.6 | -20.27 | -37.64 | Upgrade |
Net Income Growth | 711.56% | - | - | - | - | Upgrade |
Shares Outstanding (Basic) | 10 | 8 | 8 | 8 | 8 | Upgrade |
Shares Outstanding (Diluted) | 10 | 8 | 8 | 8 | 8 | Upgrade |
Shares Change (YoY) | 22.73% | - | - | - | - | Upgrade |
EPS (Basic) | 0.09 | 0.01 | -0.07 | -2.50 | -4.65 | Upgrade |
EPS (Diluted) | 0.09 | 0.01 | -0.07 | -2.50 | -4.65 | Upgrade |
EPS Growth | 750.00% | - | - | - | - | Upgrade |
Free Cash Flow | -137.91 | -3.43 | -24.1 | -2.12 | 15.63 | Upgrade |
Free Cash Flow Per Share | -13.87 | -0.42 | -2.98 | -0.26 | 1.93 | Upgrade |
Gross Margin | 3.78% | 14.27% | 27.99% | 6.94% | 10.69% | Upgrade |
Operating Margin | 0.40% | -0.34% | -3.04% | -5.41% | -38.19% | Upgrade |
Profit Margin | 0.27% | 0.23% | -3.12% | -22.74% | -39.27% | Upgrade |
Free Cash Flow Margin | -44.87% | -7.64% | -125.49% | -2.38% | 16.31% | Upgrade |
EBITDA | 1.61 | 0.23 | -0.02 | -4.02 | -34.52 | Upgrade |
EBITDA Margin | 0.53% | 0.51% | -0.12% | -4.51% | -36.02% | Upgrade |
D&A For EBITDA | 0.38 | 0.38 | 0.56 | 0.8 | 2.09 | Upgrade |
EBIT | 1.23 | -0.15 | -0.58 | -4.82 | -36.61 | Upgrade |
EBIT Margin | 0.40% | -0.34% | -3.04% | -5.41% | -38.19% | Upgrade |
Effective Tax Rate | 31.47% | 51.02% | - | - | - | Upgrade |
Revenue as Reported | 307.34 | 45.31 | 19.2 | 91.63 | 95.86 | Upgrade |
Advertising Expenses | - | 0.22 | 0.27 | 0.38 | 0.16 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.